(UroToday.com) Avelumab is an anti-PD-L1 immune checkpoint inhibitor with a native IgG1 isotype backbone that can bind Fc receptors. In the JAVELIN 100 bladder trial, Avelumab first-line maintenance + best standard of care (BSC) significantly improved overall survival (OS) vs. (BSC) alone in patients with advanced urothelial carcinoma (UC) that had not progressed on first-line platinum-based chemotherapy1. The median OS for Avelumab maintenance after BSC was 21.4 months (95% CI 18.9-26.1), while for BSC alone, it was 14.3 months (95% CI 12.9-17.9). The HR in favor of the Avelumab maintenance was 0.69 (95% CI 0.56-0.86, p<0.001).